NeuroDelta Ltd

The NeuroDelta group was established 20 years ago and used in silico identification of protein-protein interactions for subsequent development as models for drug and diagnostic discovery. The in silico identification techniques also aided in the design of specific peptide aptamers that recognised the specific molecular targets being studied.

The commercialisation plan, developed by Dr Nat Milton, for this technology won the
UCL Entrepreneur's Challenge competition in 2003. This led to the formation of the original NeuroDelta Ltd company in collaboration with Insight Biotechnology Ltd, which raised DTI funding for a project to take forward potential Alzheimer's related therapeutic and diagnostic molecules. The project combined the in silico identification techniques with laboratory expertise in protein-protein interactions relevant to Alzheimer's disease. The antisense amyloid-ß peptides plus phosphorylated amyloid-ß compounds identified by Dr Nat Milton were patented and taken to intention to grant in Europe at the end of the project in 2007.

The current
NeuroDelta Ltd company was established in 2007 to continue the NeuroDelta group commercial activity and holds intellectual property, including the UK registered neurodelta trademark, that were developed by Dr Nat Milton during his commercial work as part of the NeuroDelta group. The company also owns a number of websites linked to this activity, which have been redirected to this page. For commercial use of this intellectual property please email NeuroDelta Ltd directly.

The technologies developed by the NeuroDelta group have been widely used in the discovery of novel peptides that have been developed as potential drugs. The kissorphin KiSS-1 metastasis suppressor protein derived peptides were identified as amyloid binding and the work covered in a UK patent for the use of kissorphin peptides in the treatment of Alzheimer's disease, Creutzfeldt Jakob disease and Diabetes Mellitus, that was granted to the University of Roehampton [
GB2493313 Patent]. Compounds commercially developed from these techniques include the kissorphin peptides, which inhibit amyloid-ß, amylin and prion protein fragment induced neurotoxicity in vitro, plus the R9 peptide, which inhibits catalase interactions with amyloid-ß fibrils.


Neurodelta Ltd Contact Information:

NeuroDelta Ltd
Company number: 6222473
 Registered in England & Wales

Current NeuroDelta Ltd Information

NeuroDelta Ltd Information

Bioinformatics Protocols Site Support: